论文部分内容阅读
【目的】评价微血管密度在非小细胞肺癌中的预后意义。【方法】石蜡切片、HE染色、及CD34免疫组化方法,用Kaplan-Meier方法进行生存率分析及生存曲线的绘制,用Log-Rank检验进行生存率的比较,用Cox比例风险模型、Wald检验进行各预后因素分析。【结果】将患者按微血管密度(MVD)以均数47为界分为两组,两组生存率有显著性差异(P= 0.0186)。MVD<47组生存率高于MVD≥47组。非小细胞肺癌淋巴结转移、临床分期、微血管密度、与肺癌患者术后的生存时间有关。其对肺癌患者生存时间影响由大到小为临床分期、淋巴转移、微血管密度(P值分别为0.001、0.031、0.035)。【结论】非小细胞肺癌中微血管密度与肺癌患者临床预后显著相关,提示用CD34作标记物检测非小细胞肺癌中的MVD可以作为判断肺癌患者临床预后的重要指标。
【Objective】 To evaluate the prognostic significance of microvessel density in non-small cell lung cancer. 【Methods】 Survival analysis and survival curves were drawn by Kaplan-Meier method. Paraffin sections, HE staining and CD34 immunohistochemistry were used to compare the survival rate with Log-Rank test. The Cox proportional hazards model, Wald test The prognostic factors were analyzed. 【Results】 The patients were divided into two groups according to the mean microvessel density (MVD) 47. The survival rates of the two groups were significantly different (P = 0.0186). MVD <47 group survival rate was higher than MVD≥47 group. Non-small cell lung cancer lymph node metastasis, clinical stage, microvessel density, and lung cancer patients after the survival time. The survival time of patients with lung cancer from large to small as the clinical stage, lymph node metastasis, microvessel density (P values were 0.001,0.031,0.035). 【Conclusions】 The microvessel density in non-small cell lung cancer is significantly correlated with the clinical prognosis of patients with lung cancer, suggesting that using CD34 as a marker to detect MVD in non-small cell lung cancer can be used as an important index to judge the clinical prognosis of patients with lung cancer.